Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...

The Vaccines and Related Biological Products Advisory Committee was supposed to meet on March 13 to recommend to the agency ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Hims & Hers Health (HIMS) is an intriguing stock strategically positioned in the rapidly expanding telehealth market. However, this week’s ...